Abstract Objectives To develop and validate, a real-time algorithm to individualize unfractionated heparin (UFH) dosing based on activated clotting time (ACT) dynamics in cardiac procedures with or without cardiopulmonary bypass..
Read More
Abstract Background Protamine is administered to reverse unfractionated heparin (UFH) after cardiopulmonary bypass (CPB), but dosing strategies—typically based on protamine-to-heparin (P:H) ratios—vary, and the minimal effective dose remains unclear. Reversal..
Read More
Abstract To prevent uncontrolled activation of the hemostatic system and thrombin formation that could be triggered by cardiopulmonary bypass (CPB), unfractionated heparin (hereinafter heparin) is administered to induce profound anticoagulation. Effective..
Read More
Abstract Objectives The present study was designed to investigate the equivalence of two target activated clotting time (ACT) values with regard to packed red blood cell (PRBC) transfusion in patients..
Read More
Abstract Objectives To assess concordance between Hemochron Response (ACTr) and the three-activator device Hemochron Signature Elite (ACTe) in adult cardiac surgery patients. To evaluate the correlation between ACTe and anti-Xa..
Read More
Abstract Objectives According to the manufacturer, the Hemochron ACT-LR cuvette is designated for heparin concentrations of 0 to 2.5 IU/mL, while the optimal concentration range for the ACT+ cartridge is..
Read More
Abstract Introduction The recently recommended activated clotting time (ACT) to be maintained at the initiation of and during cardiopulmonary bypass (CPB) is ≥480 s. However, the post-unfractionated heparin (UFH) administration ACT..
Read More
Abstract OBJECTIVES Activated clotting time (ACT) is commonly used to monitor anticoagulation during cardiac surgeries. Final ACT values may be essential to predict postoperative bleeding and transfusions, although ideal values..
Read More
Abstract In unfractionated heparin (UFH) monitoring during extracorporeal circulation, the traditional measures of activated clotting time (ACT) or activated partial thromboplastin time (APTT) may diverge, confounding anticoagulant adjustments. We aimed..
Read More
Abstract Background No guidelines for administering and monitoring anticoagulants intraprocedurally are currently available in dogs, despite the prevalence of procedures necessitating systemic anticoagulation with heparin. Objectives To evaluate an activated..
Read More
Abstract Factor XII (FXII) deficiency is a congenital disorder inherited as an autosomal recessive condition. In his heterozygous form, it is relatively common in the general population. However, a total..
Read More
Abstract The interaction between the patient and the ECMO (extracorporeal membrane oxygenation) circuit initiates a significant coagulation and inflammatory response due to the large surface area of foreign material contained..
Read More
Abstract Objective To compare the incidence of bleeding and between adult venoarterial (VA) (ECMO) patients managed with an (ACT)-guided heparin protocol and activated (aPTT) protocol. Design . Setting Tertiary care, academic medical center...
Read More
Abstract Coagulation Factor XII (fXII), the Hageman factor, is a procoagulant 80kDa glycoprotein with a plasma concentration of about 40 µg/mL (approximately 500 nmol/L). Plasma fXII is mainly synthesized in..
Read More
Abstract Antiphospholipid Syndrome (APS) is an immunologic disorder that causes a state of hypercoagulability that can result in recurrent venous and arterial thromboses. Patients who experience APS may develop cardiac..
Read More
Abstract Dose adjustment of unfractionated heparin (UFH) anticoagulation is an important factor to reduce hemorrhagic events. High doses of heparin can be monitored by Activated Clotting Time (ACT). Because of..
Read More
Abstract Objective To compare immediate postoperative results in patients receiving heparin-albumin-coated and non-coated circuits. Methods A total of 241 patients undergoing on-pump cardiac surgery were divided into two groups: those..
Read More